Avadel Pharmaceuticals (NASDAQ:AVDL) Releases Earnings Results, Meets Expectations

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) released its earnings results on Monday. The company reported ($0.05) EPS for the quarter, meeting analysts' consensus estimates of ($0.05), Zacks reports. Avadel Pharmaceuticals had a negative return on equity of 93.34% and a negative net margin of 52.53%. The firm had revenue of $50.41 million for the quarter, compared to analysts' expectations of $50.03 million. Avadel Pharmaceuticals updated its FY 2025 guidance to EPS.

Avadel Pharmaceuticals Price Performance

NASDAQ AVDL traded up $0.01 during midday trading on Thursday, hitting $7.88. 791,935 shares of the company traded hands, compared to its average volume of 1,191,322. The company has a market cap of $759.33 million, a PE ratio of -9.97 and a beta of 1.28. Avadel Pharmaceuticals has a 52 week low of $7.39 and a 52 week high of $19.09. The company's 50-day simple moving average is $8.67 and its 200-day simple moving average is $11.45.

Insider Transactions at Avadel Pharmaceuticals

In other Avadel Pharmaceuticals news, CEO Gregory J. Divis purchased 9,598 shares of the business's stock in a transaction that occurred on Friday, December 6th. The shares were bought at an average price of $9.98 per share, for a total transaction of $95,788.04. Following the acquisition, the chief executive officer now owns 9,598 shares in the company, valued at $95,788.04. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Linda Palczuk purchased 5,000 shares of Avadel Pharmaceuticals stock in a transaction on Tuesday, January 21st. The shares were acquired at an average cost of $7.93 per share, with a total value of $39,650.00. Following the completion of the transaction, the director now directly owns 67,900 shares in the company, valued at $538,447. The trade was a 7.95 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 55,579 shares of company stock valued at $526,363. Corporate insiders own 4.80% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of research firms recently issued reports on AVDL. Deutsche Bank Aktiengesellschaft initiated coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They set a "buy" rating and a $12.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $21.00 target price on shares of Avadel Pharmaceuticals in a research note on Tuesday. UBS Group reduced their price target on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a "buy" rating on the stock in a research note on Monday, January 13th. Piper Sandler decreased their price objective on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an "overweight" rating for the company in a report on Friday, January 10th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 target price on shares of Avadel Pharmaceuticals in a research report on Monday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $19.88.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.